Acotec Scientific Holdings Limited (HKG:6669)

Hong Kong · Delayed Price · Currency is HKD

8.64

+0.17 (2.01%)

Jun 18, 2026, 4:08 PM HKT

18.36% (1Y)

Market Cap	2.71B +2.9%
Revenue (ttm)	717.35M +20.7%
Net Income	132.63M +128.0%
EPS	0.43 +129.4%
Shares Out	313.39M
PE Ratio	19.91
Forward PE	17.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	317,709
Open	8.69
Previous Close	8.47
Day's Range	8.18 - 8.69
52-Week Range	7.07 - 15.47
Beta	-0.03
Analysts	Strong Buy
Price Target	17.38 (+101.16%)
Earnings Date	May 26, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2011

Employees 653

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6669

Full Company Profile

Financial Performance

In 2025, HKG:6669's revenue was 644.63 million, an increase of 20.72% compared to the previous year's 533.99 million. Earnings were 119.18 million, an increase of 127.97%.

Financial numbers in CNY Financial Statements